Review





Similar Products

96
ATCC islet microvascular endothelial cell line
Stromelysin‐1 KO promotes IMEC proliferation and confers resistance to glucotoxicity. (A) Validation of stromelysin‐1 knockout. Representative immunoblot and corresponding densitometric quantification showing the depletion of stromelysin‐1 protein in knockout (KO) IMECs compared to wild‐type (WT) controls. (B) Quantification of IMEC proliferation, assessed by phase object confluence over 72 h. WT and stromelysin‐1 KO cells were cultured under normal glucose (Control, 5.6 mM), high glucose (HG, 35 mM), and HG supplemented with 10 −8 M insulin (HG + I), 0.5 mM l ‐arginine (HG + LA), or 100 μM β‐mercaptoethanol (HG + βME). Representative images at 72 h are shown. Scale bar = 100 μm. (C) Quantitative analysis of cell proliferation measured as the percentage of phase object confluence. WT, wild‐type. KO, knockout. IMECs, islet <t>microvascular</t> <t>endothelial</t> cells. Data are presented as mean ± SEM ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the corresponding WT group under the same treatment conditions.
Islet Microvascular Endothelial Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/islet microvascular endothelial cell line/product/ATCC
Average 96 stars, based on 1 article reviews
islet microvascular endothelial cell line - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

94
Miltenyi Biotec islet cells
Stromelysin‐1 KO promotes IMEC proliferation and confers resistance to glucotoxicity. (A) Validation of stromelysin‐1 knockout. Representative immunoblot and corresponding densitometric quantification showing the depletion of stromelysin‐1 protein in knockout (KO) IMECs compared to wild‐type (WT) controls. (B) Quantification of IMEC proliferation, assessed by phase object confluence over 72 h. WT and stromelysin‐1 KO cells were cultured under normal glucose (Control, 5.6 mM), high glucose (HG, 35 mM), and HG supplemented with 10 −8 M insulin (HG + I), 0.5 mM l ‐arginine (HG + LA), or 100 μM β‐mercaptoethanol (HG + βME). Representative images at 72 h are shown. Scale bar = 100 μm. (C) Quantitative analysis of cell proliferation measured as the percentage of phase object confluence. WT, wild‐type. KO, knockout. IMECs, islet <t>microvascular</t> <t>endothelial</t> cells. Data are presented as mean ± SEM ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the corresponding WT group under the same treatment conditions.
Islet Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/islet cells/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
islet cells - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

86
Sana Biotechnology Inc hip modified islet cells
Stromelysin‐1 KO promotes IMEC proliferation and confers resistance to glucotoxicity. (A) Validation of stromelysin‐1 knockout. Representative immunoblot and corresponding densitometric quantification showing the depletion of stromelysin‐1 protein in knockout (KO) IMECs compared to wild‐type (WT) controls. (B) Quantification of IMEC proliferation, assessed by phase object confluence over 72 h. WT and stromelysin‐1 KO cells were cultured under normal glucose (Control, 5.6 mM), high glucose (HG, 35 mM), and HG supplemented with 10 −8 M insulin (HG + I), 0.5 mM l ‐arginine (HG + LA), or 100 μM β‐mercaptoethanol (HG + βME). Representative images at 72 h are shown. Scale bar = 100 μm. (C) Quantitative analysis of cell proliferation measured as the percentage of phase object confluence. WT, wild‐type. KO, knockout. IMECs, islet <t>microvascular</t> <t>endothelial</t> cells. Data are presented as mean ± SEM ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the corresponding WT group under the same treatment conditions.
Hip Modified Islet Cells, supplied by Sana Biotechnology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hip modified islet cells/product/Sana Biotechnology Inc
Average 86 stars, based on 1 article reviews
hip modified islet cells - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Vertex Pharmaceuticals islet cells
Stromelysin‐1 KO promotes IMEC proliferation and confers resistance to glucotoxicity. (A) Validation of stromelysin‐1 knockout. Representative immunoblot and corresponding densitometric quantification showing the depletion of stromelysin‐1 protein in knockout (KO) IMECs compared to wild‐type (WT) controls. (B) Quantification of IMEC proliferation, assessed by phase object confluence over 72 h. WT and stromelysin‐1 KO cells were cultured under normal glucose (Control, 5.6 mM), high glucose (HG, 35 mM), and HG supplemented with 10 −8 M insulin (HG + I), 0.5 mM l ‐arginine (HG + LA), or 100 μM β‐mercaptoethanol (HG + βME). Representative images at 72 h are shown. Scale bar = 100 μm. (C) Quantitative analysis of cell proliferation measured as the percentage of phase object confluence. WT, wild‐type. KO, knockout. IMECs, islet <t>microvascular</t> <t>endothelial</t> cells. Data are presented as mean ± SEM ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the corresponding WT group under the same treatment conditions.
Islet Cells, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/islet cells/product/Vertex Pharmaceuticals
Average 86 stars, based on 1 article reviews
islet cells - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

98
Beijing Solarbio Science rat islet tumor cells
Stromelysin‐1 KO promotes IMEC proliferation and confers resistance to glucotoxicity. (A) Validation of stromelysin‐1 knockout. Representative immunoblot and corresponding densitometric quantification showing the depletion of stromelysin‐1 protein in knockout (KO) IMECs compared to wild‐type (WT) controls. (B) Quantification of IMEC proliferation, assessed by phase object confluence over 72 h. WT and stromelysin‐1 KO cells were cultured under normal glucose (Control, 5.6 mM), high glucose (HG, 35 mM), and HG supplemented with 10 −8 M insulin (HG + I), 0.5 mM l ‐arginine (HG + LA), or 100 μM β‐mercaptoethanol (HG + βME). Representative images at 72 h are shown. Scale bar = 100 μm. (C) Quantitative analysis of cell proliferation measured as the percentage of phase object confluence. WT, wild‐type. KO, knockout. IMECs, islet <t>microvascular</t> <t>endothelial</t> cells. Data are presented as mean ± SEM ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the corresponding WT group under the same treatment conditions.
Rat Islet Tumor Cells, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat islet tumor cells/product/Beijing Solarbio Science
Average 98 stars, based on 1 article reviews
rat islet tumor cells - by Bioz Stars, 2026-06
98/100 stars
  Buy from Supplier

86
Vertex Pharmaceuticals stem cell derived islets
Evolution of <t>stem</t> <t>cell–derived</t> beta-cell therapy.
Stem Cell Derived Islets, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stem cell derived islets/product/Vertex Pharmaceuticals
Average 86 stars, based on 1 article reviews
stem cell derived islets - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Vertex Pharmaceuticals stem cell derived islet cell therapy
Evolution of <t>stem</t> <t>cell–derived</t> beta-cell therapy.
Stem Cell Derived Islet Cell Therapy, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stem cell derived islet cell therapy/product/Vertex Pharmaceuticals
Average 86 stars, based on 1 article reviews
stem cell derived islet cell therapy - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

96
ATCC murine islet derived ms1 endothelial cells
Evolution of <t>stem</t> <t>cell–derived</t> beta-cell therapy.
Murine Islet Derived Ms1 Endothelial Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine islet derived ms1 endothelial cells/product/ATCC
Average 96 stars, based on 1 article reviews
murine islet derived ms1 endothelial cells - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

Image Search Results


Stromelysin‐1 KO promotes IMEC proliferation and confers resistance to glucotoxicity. (A) Validation of stromelysin‐1 knockout. Representative immunoblot and corresponding densitometric quantification showing the depletion of stromelysin‐1 protein in knockout (KO) IMECs compared to wild‐type (WT) controls. (B) Quantification of IMEC proliferation, assessed by phase object confluence over 72 h. WT and stromelysin‐1 KO cells were cultured under normal glucose (Control, 5.6 mM), high glucose (HG, 35 mM), and HG supplemented with 10 −8 M insulin (HG + I), 0.5 mM l ‐arginine (HG + LA), or 100 μM β‐mercaptoethanol (HG + βME). Representative images at 72 h are shown. Scale bar = 100 μm. (C) Quantitative analysis of cell proliferation measured as the percentage of phase object confluence. WT, wild‐type. KO, knockout. IMECs, islet microvascular endothelial cells. Data are presented as mean ± SEM ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the corresponding WT group under the same treatment conditions.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Consequences of CRISPR ‐Cas9‐Mediated Stromelysin‐1 Knockout in Pancreatic Islet Microvascular Endothelial Cells

doi: 10.1111/jcmm.71098

Figure Lengend Snippet: Stromelysin‐1 KO promotes IMEC proliferation and confers resistance to glucotoxicity. (A) Validation of stromelysin‐1 knockout. Representative immunoblot and corresponding densitometric quantification showing the depletion of stromelysin‐1 protein in knockout (KO) IMECs compared to wild‐type (WT) controls. (B) Quantification of IMEC proliferation, assessed by phase object confluence over 72 h. WT and stromelysin‐1 KO cells were cultured under normal glucose (Control, 5.6 mM), high glucose (HG, 35 mM), and HG supplemented with 10 −8 M insulin (HG + I), 0.5 mM l ‐arginine (HG + LA), or 100 μM β‐mercaptoethanol (HG + βME). Representative images at 72 h are shown. Scale bar = 100 μm. (C) Quantitative analysis of cell proliferation measured as the percentage of phase object confluence. WT, wild‐type. KO, knockout. IMECs, islet microvascular endothelial cells. Data are presented as mean ± SEM ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the corresponding WT group under the same treatment conditions.

Article Snippet: A pancreatic islet microvascular endothelial cell line (MS1; ATCC, Manassas, VA, USA) was employed in the present study, and its culture was performed in specifically formulated media.

Techniques: Biomarker Discovery, Knock-Out, Western Blot, Cell Culture, Control

Stromelysin‐1 KO enhances the migratory capacity of IMECs in a wound healing assay. (A) Representative images of a scratch wound healing assay at 0, 24, and 48 h. WT and stromelysin‐1 KO IMECs were subjected to Control (5.6 mM glucose), HG (35 mM glucose), HG + I (insulin, 10 −8 M), HG + LA ( l ‐arginine, 0.5 mM), and HG + βME (β‐mercaptoethanol, 100 μM), respectively. Scale bar = 100 μm. (B) Quantification of wound closure, presented as relative wound confluence at 24 and 48 h. WT, wild‐type. KO, knockout. IMECs, islet microvascular endothelial cells. Data are presented as mean ± SEM from three independent experiments. * p < 0.05, ** p < 0.01, *** p <0.001, **** p < 0.0001 compared with the corresponding WT group.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Consequences of CRISPR ‐Cas9‐Mediated Stromelysin‐1 Knockout in Pancreatic Islet Microvascular Endothelial Cells

doi: 10.1111/jcmm.71098

Figure Lengend Snippet: Stromelysin‐1 KO enhances the migratory capacity of IMECs in a wound healing assay. (A) Representative images of a scratch wound healing assay at 0, 24, and 48 h. WT and stromelysin‐1 KO IMECs were subjected to Control (5.6 mM glucose), HG (35 mM glucose), HG + I (insulin, 10 −8 M), HG + LA ( l ‐arginine, 0.5 mM), and HG + βME (β‐mercaptoethanol, 100 μM), respectively. Scale bar = 100 μm. (B) Quantification of wound closure, presented as relative wound confluence at 24 and 48 h. WT, wild‐type. KO, knockout. IMECs, islet microvascular endothelial cells. Data are presented as mean ± SEM from three independent experiments. * p < 0.05, ** p < 0.01, *** p <0.001, **** p < 0.0001 compared with the corresponding WT group.

Article Snippet: A pancreatic islet microvascular endothelial cell line (MS1; ATCC, Manassas, VA, USA) was employed in the present study, and its culture was performed in specifically formulated media.

Techniques: Wound Healing Assay, Control, Knock-Out

Stromelysin‐1 KO restores endothelial barrier integrity and attenuates glucotoxicity‐induced hyperpermeability. (A) Experimental groups and treatment conditions. (B) Schematic of the transwell‐based permeability assay. Confluent IMEC monolayers were exposed to the treatment media for 24 h, and the passage of 2 mg/mL FITC‐dextran from the upper to the lower chamber was measured over time. (C) Quantification of FITC‐dextran flux across IMEC monolayers over 90 min. Data show fluorescence intensity in the lower chamber, normalised to the baseline at t = 0. WT, wild‐type. KO, knockout. IMECs, islet microvascular endothelial cells. Control (5.6 mM glucose), HG (35 mM glucose), HG + I (insulin, 10 −8 M), HG + LA ( l ‐arginine, 0.5 mM), and HG + βME (100 μM). Data are expressed as mean ± SEM, n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, compared with corresponding WT group.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Consequences of CRISPR ‐Cas9‐Mediated Stromelysin‐1 Knockout in Pancreatic Islet Microvascular Endothelial Cells

doi: 10.1111/jcmm.71098

Figure Lengend Snippet: Stromelysin‐1 KO restores endothelial barrier integrity and attenuates glucotoxicity‐induced hyperpermeability. (A) Experimental groups and treatment conditions. (B) Schematic of the transwell‐based permeability assay. Confluent IMEC monolayers were exposed to the treatment media for 24 h, and the passage of 2 mg/mL FITC‐dextran from the upper to the lower chamber was measured over time. (C) Quantification of FITC‐dextran flux across IMEC monolayers over 90 min. Data show fluorescence intensity in the lower chamber, normalised to the baseline at t = 0. WT, wild‐type. KO, knockout. IMECs, islet microvascular endothelial cells. Control (5.6 mM glucose), HG (35 mM glucose), HG + I (insulin, 10 −8 M), HG + LA ( l ‐arginine, 0.5 mM), and HG + βME (100 μM). Data are expressed as mean ± SEM, n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, compared with corresponding WT group.

Article Snippet: A pancreatic islet microvascular endothelial cell line (MS1; ATCC, Manassas, VA, USA) was employed in the present study, and its culture was performed in specifically formulated media.

Techniques: Permeability, Fluorescence, Knock-Out, Control

Stromelysin‐1 KO remodels the secretome of IMECs towards a pro‐stabilisation profile. (A) Representative cytokine array membranes comparing the secretomes of WT and stromelysin‐1 KO IMECs under 5.6 mM glucose (Control), 35 mM glucose (HG), 35 mM glucose plus 10 −8 M insulin (HG + I), 35 mM glucose plus 0.5 mM l ‐arginine (HG + LA) and 35 mM glucose plus 100 μM β‐mercaptoethanol (HG + βME). Black boxes highlight proteins with significant differential expression. Reference spots were used for signal normalisation. (B) Densitometric quantification of differentially secreted proteins. WT, wild‐type. KO, knockout. IMECs, islet microvascular endothelial cells. Data are expressed as mean ± SEM, n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared with corresponding WT IMECs.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Consequences of CRISPR ‐Cas9‐Mediated Stromelysin‐1 Knockout in Pancreatic Islet Microvascular Endothelial Cells

doi: 10.1111/jcmm.71098

Figure Lengend Snippet: Stromelysin‐1 KO remodels the secretome of IMECs towards a pro‐stabilisation profile. (A) Representative cytokine array membranes comparing the secretomes of WT and stromelysin‐1 KO IMECs under 5.6 mM glucose (Control), 35 mM glucose (HG), 35 mM glucose plus 10 −8 M insulin (HG + I), 35 mM glucose plus 0.5 mM l ‐arginine (HG + LA) and 35 mM glucose plus 100 μM β‐mercaptoethanol (HG + βME). Black boxes highlight proteins with significant differential expression. Reference spots were used for signal normalisation. (B) Densitometric quantification of differentially secreted proteins. WT, wild‐type. KO, knockout. IMECs, islet microvascular endothelial cells. Data are expressed as mean ± SEM, n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared with corresponding WT IMECs.

Article Snippet: A pancreatic islet microvascular endothelial cell line (MS1; ATCC, Manassas, VA, USA) was employed in the present study, and its culture was performed in specifically formulated media.

Techniques: Control, Quantitative Proteomics, Knock-Out

Evolution of stem cell–derived beta-cell therapy.

Journal: Cell Transplantation

Article Title: Advances in stem cell–derived beta-cell therapy: A new frontier in type 1 diabetes treatment

doi: 10.1177/09636897261417623

Figure Lengend Snippet: Evolution of stem cell–derived beta-cell therapy.

Article Snippet: More recently, Vertex Pharmaceuticals reported reproducible clinical benefit using fully differentiated stem cell–derived islets (VX-880), showing partial to complete insulin independence in multiple participants .

Techniques: Derivative Assay